CDC's recommendation of Truvada for HIV pre-exposure prophylaxis is unlikely to trigger an explosion in prescriptions for the drug, despite estimates that as many as half a million people could be candidates in the U.S.

If all those candidates actually got the drug for one year, the cost would be $7.8 billion. But that is unlikely to happen, because CDC's recommendation does not address several of the barriers that have limited uptake.